• Systematic and continuous assessment and documentation of side effects and adverse events occurring under psychopharmacologic treatment, as well as cross-sectional assessments of prescribing patterns. This focus is in cooperation with the Österreichische Gesellschaft für Arzneimittelsicherheit in der Psychiatrie (ÖAMSP)
  
  

• Neuroimaging withPET, PET/MR, MRT, fMRT, MRS, SPECT, EEG
• Quantification of levels of specific proteins in the brain (i.e., serotonin-1A-receptors, NMDA-receptors, dopamin-2/3-Receptors, monoamine transporters (SERT, NET), enzymes (MAOA) with PET in psychiatric disorders (i.e., depression, anxiety disorders, schizophrenia, ADHD) as well as treatment-induced changes.
• Quantification of the occupancy of psychopharmaceuticals at specific targets in the brain and assessment of the association with functional changes (i.e., neuronal network alterations)
• Quantification of glucose and neurotransmitter metabolism in the brain (i.e., with the radioligands FDOPA and FDG), also simultaneously with fMRI
• Assessment of perfusion (pcASL) with PET/MR for differentiation of glucose metabolism and neuronal activity during cognitive or emotional tasks or psychopharmacological stimulation
• Imaging genetics: assessment of the relationship between genetic variants, epigenetics (i.e., mRNA, methylome), and protein levels in various psychiatric disorders and in association with functional and structural changes
• Assessment and testing of neuroimaging-based prediction parameters for treatment and early detection
• Assessment and testing of neuroimaging-based prediction parameters for differential diagnostics and subgroup-classification
• fMRI for the assessment of neuronal activation patterns in psychiatric disorders and in accordance with emotional and cognitive tasks
• FMRI for the assessment of neuronal connectivity patterns in psychiatric disorders and specific therapies (i.e, psychopharmacology, TMS, ECT)
• MRI for the quantification of glutamate/glutamine and GABA in various psychiatric disorders and in association with various treatments (i.e., ketamine, TMS, SSRIs)
• Brain morphometry (voxel- and parcellation-based) including assessment of hippocampus substructures, amygdala, thalamus, brainstem, and cortex in the context of psychiatric disorders and treatment
• Assessment of the glymphatic system during sleep and under psychopharmacologic treatment utilizing PET/MR/EEG

• The study of light therapy and therapeutic sleep deprivation as non-pharmacologic biologic treatment measures
• Chronobiologic characteristics of psychiatric disorders, particularly affective disorders
• Seasonal affective disorder

• Study of antidepressants (i.e., SSRIs and ketamine) utilizing a broad array of imaging methods (i.e., PET, MRS, fMRI…)
• Treatment optimization in TMS using imaging-supported stimulation based on structural and functional data
• Research on light therapy and therapeutic sleep deprivation using imaging (i.e., MAOA PET, fMRI)
• Study of seasonal affective disorder using methods for the assessment of brain structure and protein concentrations

• Research to support the definition of treatment response, non-response, and resistance
• Research to support the definition of pseudo-resistance
• Algorithms for antidepressant therapy
• Psychopharmacotherapeutic strategies in non-response and resistance
• Clinical and genetic correlates of non-response and resistance
• Clinical and genetic correlates of „difficult-to-treat depression" (DTD)“
• Research on the impact of socio-demographic factors and clinical variables on treatment response

• Efficacy and tolerability of psychopharmaceuticals
• Assessment of study methodology in psychopharmacologic studies with a focus on placebo response
• Meta-Analyses

• Genetic and epigenetic studies in various neuropsychiatric disorders including affective disorders, schizophrenia, Gilles de la Tourette Syndrome, eating disorders, etc.
• Genetic and epigenetic studies in suicidality in affective disorders
• Studies on gene-environment interaction
• Pharmacogenetic studies on response and side effects in various psychiatric disorders

• Treatment concepts
• Assessment of the toxicity of pschopharmaceuticals
• The study of involuntary admission and treatment in the context of the “Unterbringungsgesetz”
• Treatment response and imaging of electroconvulsive therapy with PET/MR (serotonin-1A-receptors, MAO-A, volumetric analysis) and plasma markers (BDNF)

• Assessment of new psychopharmaceuticals in regards to their efficacy and tolerability
• Assessment of clinical and biological treatment markers
• Assessment of the relationship between genetic variables, response, and tolerability
• Assessment of challenging clinical phenomena and treatment resistance as well as treatment strategies

• Impact of sensitization, schizophrenia, and genetic parameters on dopamine metabolism
• Sex differences in dopamine metabolism in patients with schizophrenia and healthy controls
• Structural characteristics of the cortex and their impact on dopamine release in schizophrenia, assessed with PET/MR
• Impact of omega-3-fatty acids on dopamine metabolism and working memory in patients with first-episode psychosis, persons at high risk, and healthy controls
• Assessment of amphetamine-induced sensitization on dopamine synthesis and release
• Prediction studies in first-episode psychosis
• Sex and gender aspects of auditory hallucinations in schizophrenic disorders
• Translation and validation of the questionnaire „BAVQ-R"
• Translation and validation of the questionnaire „VPD" (Voice Power Differential Scale)
• The influence of ToM -disorders on reaching personal goals in patients with schizophrenia (Pilot study)

• Studies on the diagnosis and treatment of substance use disorders and non-substance use disorders
• Influence of somatic and psychiatric comorbidities on the course of substance use disorders
• Treatment accessibility studies for substance use disorders in incarceration
• Impact of opiate substitution therapy on intrauterine development
• Hotline for patients with gambling addiction

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.